Stay updated with breaking news from Nasdaq Itos. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DekaBank Deutsche Girozentrale lifted its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) by 9.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,300 shares of the company’s stock after acquiring an additional 1,000 shares during the quarter. […]
ITeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) Director David Hallal sold 1,171 shares of the business’s stock in a transaction on Thursday, June 9th. The stock was sold at an average price of $19.51, for a total transaction of $22,846.21. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which […]
Equities analysts expect that iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) will report earnings per share (EPS) of $1.20 for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for iTeos Therapeutics’ earnings, with the lowest EPS estimate coming in at $0.08 and the highest estimate coming in at $3.13. iTeos […]
ITeos Therapeutics (NASDAQ:ITOS – Get Rating) released its earnings results on Thursday. The company reported $1.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.80 by $1.02, reports. The firm had revenue of $152.52 million for the quarter, compared to the consensus estimate of $63.30 million. ITOS stock traded up $0.01 […]
Wall Street brokerages expect that iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) will announce $63.30 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for iTeos Therapeutics’ earnings, with estimates ranging from $40.00 million to $78.10 million. The business is scheduled to issue its next earnings results […]